Around 30% of admitted patients with COVID-19 pneumonia develop a hyper-inflammatory state
whose progression to an acute respiratory distress syndrome (ARSD) could be prevented by the
early initiation of immune-modulatory agents. The role of glucocorticoids (GC) in this
setting remains controversial. This study aims to assess the safety and effectiveness of GC
pulses to improve the clinical outcomes of patients with COVID-19 pneumonia with risen
inflammatory biomarkers.
Phase:
Phase 3
Details
Lead Sponsor:
Fundacion Miguel Servet
Collaborators:
Complejo Hospitalario de Navarra Hospital Sant Joan Despí Moisès Broggi